Newer Anticoagulants for Non-Valvular Atrial Fibrillation
Abstract
:1. Introduction
2. Ximelagatran
3. Idraparinux
4. Dabigatran
5. Rivaroxaban
6. Apixaban
7. Other Agents
8. Conclusions
Conflict of Interest
References and Notes
- Wolf, P.A.; Dawber, T.R.; Thomas, H.E., Jr.; Kannel, W.B. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study. Neurology 1978, 28, 973–977. [Google Scholar]
- Wolf, P.A.; Abbott, R.D.; Kannel, W.B. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch. Intern. Med. 1987, 147, 1561–1564. [Google Scholar] [CrossRef]
- Kannel, W.B.; Abbott, R.D.; Savage, D.D.; McNamara, P.M. Epidemiologic features of chronic atrial fibrillation: The Framingham study. N. Engl. J. Med. 1982, 306, 1018–1022. [Google Scholar]
- Aronow, W.S.; Ahn, C.; Gutstein, H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J. Am. Geriatr. Soc. 1996, 44, 521–523. [Google Scholar]
- Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N. Engl. J. Med. 1990, 322, 863–868.
- Atrial fibrillation investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 1994, 154, 1449–1457. [CrossRef]
- Hart, R.G.; Pearce, L.A.; Aguilar, M.I. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 2007, 146, 857–867. [Google Scholar]
- Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 1998, 279, 1273–1277. [CrossRef]
- Gage, B.F.; Waterman, A.D.; Shannon, W.; Boechler, M.; Rich, M.W.; Radford, M.J. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001, 285, 2864–2870. [Google Scholar]
- Lip, G.Y.; Nieuwlaat, R.; Pisters, R.; Lane, D.A.; Crijns, H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 2010, 137, 263–272. [Google Scholar]
- Fuster, V.; Ryden, L.E.; Cannom, D.S.; Crijns, H.J.; Curtis, A.B.; Ellenbogen, K.A.; Halperin, J.L.; Kay, G.N.; Le Huezey, J.; Lowe, J.E.; et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2011, 57, e101–e198. [Google Scholar]
- Kuzniatsova, N.; Lip, G.Y. New concepts and approaches to stroke prevention in the new European Society of Cardiology guidelines for the management of atrial fibrillation. Expert Rev. Cardiovasc. Ther. 2010, 8, 1643–1647. [Google Scholar]
- Rose, A.J.; Hylek, E.M.; Ozonoff, A.; Ash, A.S.; Reisman, J.I.; Berlowitz, D.R. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: Results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ. Cardiovasc. Qual. Outcomes 2011, 4, 22–29. [Google Scholar]
- Connolly, S.J.; Pogue, J.; Eikelboom, J.; Flaker, G.; Commerford, P.; Franzosi, M.G.; Healey, J.S.; Yusuf, S. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008, 118, 2029–2037. [Google Scholar]
- Hylek, E.M.; Evans-Molina, C.; Shea, C.; Henault, L.E.; Regan, S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115, 2689–2696. [Google Scholar]
- Birman-Deych, E.; Radford, M.J.; Nilasena, D.S.; Gage, B.F. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006, 37, 1070–1074. [Google Scholar]
- Go, A.S.; Hylek, E.M.; Borowsky, L.H.; Phillips, K.A.; Selby, J.V.; Singer, D.E. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann. Intern. Med. 1999, 131, 927–934. [Google Scholar]
- Piccini, J.P.; Hernandez, A.F.; Zhao, X.; Patel, M.R.; Lewis, W.R.; Peterson, E.D.; Fonarow, G.C. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J. Am. Coll. Cardiol. 2009, 54, 1280–1289. [Google Scholar]
- Albers, G.W.; Yim, J.M.; Belew, K.M.; Bittar, N.; Hattemer, C.R.; Phillips, B.G.; Kemp, S.; Hall, E.A.; Morton, D.J.; Vlasses, P.H. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch. Intern. Med. 1996, 156, 2311–2316. [Google Scholar]
- Connolly, S.; Pogue, J.; Hart, R.; Pfeffer, M.; Hohnloser, S.; Chrolavicius, S.; Yusuf, S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006, 367, 1903–1912. [Google Scholar]
- Connolly, S.J.; Pogue, J.; Chrolavicius, S.; Hart, R.; Pfeffer, M.; Hohnloser, S.; Yusuf, S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 2009, 360, 2066–2078. [Google Scholar]
- Olsson, S.B.; Halperin, J.L.; Albers, G.W.; Diener, H.C.; Grind, M.; Horrow, J.; Petersen, P.; Vahanian, A.; Frison, L.; Nevinson, M.; et al. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 2003, 362, 1691–1698. [Google Scholar]
- Albers, G.W.; Diener, H.C.; Frison, L.; Grind, M.; Nevinson, M.; Partridge, S.; Halperin, J.L.; Horrow, J.; Olsson, S.B.; Petersen, P.; et al. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA 2005, 293, 690–698. [Google Scholar]
- Diener, H.C.; Albers, G.W.; Grind, M.; Halperin, J.L.; Horrow, J.; Olsson, S.B.; Petersen, P.; Vahanian, A.; Frison, L.; Nevinson, M.; et al. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc. Dis. 2006, 21, 279–293. [Google Scholar] [CrossRef]
- Bousser, M.G.; Bouthier, J.; Buller, H.R.; Cohen, A.T.; Crijns, H.; Davidson, B.L.; Halperin, J.; Hankey, G.; Levy, S.; Pengo, V.; et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: A randomised, open-label, non-inferiority trial. Lancet 2008, 371, 315–321. [Google Scholar]
- Ezekowitz, M.D.; Reilly, P.A.; Nehmiz, G.; Simmers, T.A.; Nagarakanti, R.; Parcham-Azad, K.; Pedersen, K.E.; Lionetti, D.A.; Stangier, J.; Wallentin, L. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol. 2007, 100, 1419–1426. [Google Scholar]
- Ezekowitz, M.D.; Connolly, S.; Parekh, A.; Reilly, P.A.; Varrone, J.; Wang, S.; Oldgren, J.; Themeles, E.; Wallentin, L.; Yusuf, S. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am. Heart J. 2009, 157, 805–810. [Google Scholar] [CrossRef]
- Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A.; Themeles, E.; Varrone, J.; et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009, 361, 1139–1151. [Google Scholar]
- Oldgren, J.; Alings, M.; Darius, H.; Diener, H.C.; Eikelboom, J.; Ezekowitz, M.D.; Kamensky, G.; Reilly, P.A.; Yang, S.; Yusuf, S.; et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: A subgroup analysis of the RE-LY trial. Ann. Intern. Med. 2011, 155, 660–667. [Google Scholar]
- Wallentin, L.; Yusuf, S.; Ezekowitz, M.D.; Alings, M.; Flather, M.; Franzosi, M.G.; Pais, P.; Dans, A.; Eikelboom, J.; Oldgren, J.; et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: An analysis of the RE-LY trial. Lancet 2010, 376, 975–983. [Google Scholar]
- Beasley, B.N.; Unger, E.F.; Temple, R. Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran. N. Engl. J. Med. 2011, 364, 1788–1790. [Google Scholar]
- ROCKET AF study investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and design of the ROCKET AF study. Am. Heart J. 2010, 159, 340–347. [CrossRef]
- Patel, M.R.; Mahaffey, K.W.; Garg, J.; Pan, G.; Singer, D.E.; Hacke, W.; Breithardt, G.; Halperin, J.L.; Hankey, G.J.; Piccini, J.P.; et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011, 365, 883–891. [Google Scholar]
- Connolly, S.J.; Eikelboom, J.; Joyner, C.; Diener, H.C.; Hart, R.; Golitsyn, S.; Flaker, G.; Avezum, A.; Hohnloser, S.H.; Diaz, R.; et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 2011, 364, 806–817. [Google Scholar]
- Granger, C.B.; Alexander, J.H.; McMurray, J.J.; Lopes, R.D.; Hylek, E.M.; Hanna, M.; Al-Khalidi, H.R.; Ansell, J.; Atar, D.; Avezum, A.; et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011, 365, 981–992. [Google Scholar]
- Drugs.com. Available online: http://www.drugs.com/nda/eliquis_111129.html/ (accessed on 28 April 2012).
- Weitz, J.I.; Connolly, S.J.; Patel, I.; Salazar, D.; Rohatagi, S.; Mendell, J.; Kastrissios, H.; Jin, J.; Kunitada, S. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb. Haemost. 2010, 104, 633–641. [Google Scholar] [CrossRef]
- Bassand, J.P. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace 2012, 14, 312–324. [Google Scholar]
- Steffel, J.; Braunwald, E. Novel oral anticoagulants: Focus on stroke prevention and treatment of venous thrombo-embolism. Eur. Heart J. 2011, 32, 1968–1976. [Google Scholar]
- Deedwania, P.C.; Huang, G.W. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation. Am. J. Cardiovasc. Drugs 2011, 11, 265–275. [Google Scholar]
- Ruff, C.T.; Giugliano, R.P.; Antman, E.M.; Crugnale, S.E.; Bocanegra, T.; Mercuri, M.; Hanyok, J.; Patel, I.; Shi, M.; Salazar, D.; et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am. Heart J. 2010, 160, 635–641. [Google Scholar] [CrossRef]
- Schirmer, S.H.; Baumhakel, M.; Neuberger, H.R.; Hohnloser, S.H.; van Gelder, I.C.; Lip, G.Y.H.; Bohm, M. Novel anticoagulants for stroke prevention in atrial fibrillation: Current clinical evidence and future developments. J. Am. Coll. Cardiol. 2010, 56, 2067–2076. [Google Scholar]
- Cabral, K.P.; Ansell, J. Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation. Nat. Rev. Cardiol. 2012. [Google Scholar]
- Adcock, A.K.; Lee-Iannotti, J.K.; Aguilar, M.I.; Hoffman-Snyder, C.R.; Wingerchuk, D.M.; Wellik, D.E.; Demaerschalk, B.M. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. Neurologist 2012, 18, 102–107. [Google Scholar]
- Kamel, H.; Johnston, S.C.; Easton, J.D.; Kim, A.S. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012, 43, 881–883. [Google Scholar]
- Kansal, A.R.; Sorensen, S.V.; Gani, R.; Robinson, P.; Pan, F.; Plumb, J.M.; Cowie, M.R. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012, 98, 573–578. [Google Scholar]
- Langkilde, L.K.; Asmussen, M.B.; Overgaard, M. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark. J. Med. Econ. 2012. [Google Scholar]
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Harburger, J.M.; Aronow, W.S. Newer Anticoagulants for Non-Valvular Atrial Fibrillation. Pharmaceuticals 2012, 5, 469-480. https://doi.org/10.3390/ph5050469
Harburger JM, Aronow WS. Newer Anticoagulants for Non-Valvular Atrial Fibrillation. Pharmaceuticals. 2012; 5(5):469-480. https://doi.org/10.3390/ph5050469
Chicago/Turabian StyleHarburger, Joseph M., and Wilbert S. Aronow. 2012. "Newer Anticoagulants for Non-Valvular Atrial Fibrillation" Pharmaceuticals 5, no. 5: 469-480. https://doi.org/10.3390/ph5050469